GenFleet Therapeutics (Shanghai) Inc. (GENFLEET-B) has released its Monthly Return for Equity Issuer covering the period to 30 September 2026. Key disclosures are as follows:

Share capital structure • Issued share capital stood at 351.63 million shares, split between 350.64 million H-shares listed on the Hong Kong Stock Exchange and 32.34 million unlisted domestic shares. • Par value for all shares remains RMB 0.10, keeping registered share capital at RMB 38.40 million.

September share movement • Outstanding H-shares (excluding treasury shares) decreased by 0.28% month-on-month after the company repurchased 0.99 million shares on 11 May 2026, which are now held as treasury stock. • Post-repurchase, treasury shares total 0.99 million, while issued H-shares outstanding stand at 350.64 million. • No new shares, options, warrants, or convertible securities were issued during the month; unlisted domestic share capital was unchanged.

Public float compliance • Despite the share buy-back, GenFleet confirmed compliance with the Hong Kong Main Board’s minimum public-float requirement of 19.86% for its H-share class, based on publicly available information.

Capital management outlook The modest repurchase reflects the company’s ongoing capital management initiatives. With total issued share capital unchanged and public-float adequacy reconfirmed, GenFleet retains financial flexibility for future strategic actions while marginally enhancing per-share metrics through a reduced share count.